Member Info for OAPK20

-18 outside, you reckon their drilling 🥶

This is worldwide. If only there was a test available. FDA need to get their finger out their farter and make a decision about CARDIO inCode-Score® (CIC-SCORE) De Novo submission.

Silence on this from the CEO is destroying sentiment here. Too busy liking Oberon comments on LinkedIn.

“Cardiovascular disease (CVD) is the leading cause of death among women, yet its risks during menopause often go untreated. Menopause increases CVD risk 2/3 fold through hormonal, metabolic, and lifestyle changes.

➡Over 18.6 million UK women are menopausal age, with 3.7 million living with CVD.

➡24% of female deaths in the UK are due to CVD, 99% occurring after age 45.

Our blog uncovers the critical connection between menopause and heart health, offering insights on why CVD must be a priority in menopause care. “

Ilwella Pty Ltd Upped to 15.55%. RNS 19/11/24

Take a look at the Flannery family behind Ilwella. Wonder what their end goal is here. Certainly have expertise.

“Brian Flannery, with a net worth of $1.1 billion, is one of Australia’s most successful small cap investors, with a portfolio of mining, energy, property, aged-care and biotech stocks. His success began back in 2009 with the sale of Felix Resources to Yanzhou Coal, from which he made over $500 million.“

Copper Set to Shine: UBS Forecasts Price Surge to $11,000 by 2025 Amid Supply Constraints and Strong Demand

https://stockinvest.us/digest/copper-set-to-shine-ubs-forecasts-price-surge-to-11000-by-2025-amid-supply-constraints-and-strong-demand

Indeed

3p

What’s the coding and pricing 2025?

From the last placing RNS. Likely revenues if FDA approval is ever given could be around $646M if 1/10th of those likely to be prescribed CIC-Score by their physician.

“CARDIO inCode has received CPT PLA coding (0401U) approved by American Medical Association and received positive support from the Centers for Medicare and Medicaid Services (CMS) for a price of $760/test with reimbursement discussions ongoing with the CMS for pricing inclusion the Clinical Lab Fee Schedule. “

“Market scoping interviews undertaken with potential prescribers of CARDIO inCode indicate an initial US target market of 21 million patients of which 8.5 million would likely be prescribed CiC-SCORE by their physician, if covered by insurance.“

Depends if they ve spent the lot or held some back.

The use of proceeds will be:

US regulatory, reimbursement, and commercialisation program GBP1.75m

EU expansion program GBP0.75m

UK Expansion program GBP0.75m

Corporate costs for runway to Q1 2025 GBP0.75M

Even with FDA approval, unless sales have exceeded expectations it’s hard to see a raise at a higher level. Interest just isn’t here.

Have Cavendish been in touch Tech ?

Https://www.cvdprevent.nhs.uk/outputs

For any interested. GENI ? FDA update ?

The missing piece perhaps? CEO must confirm all Additional Information has been submitted to the FDA and their decision is pending. That info must be communicated to shareholders.

Clinical trial diversity initiatives and multiregional strategies can be complementary, according to an article by FDA experts just posted in the New England Journal of Medicine. "When Diversity Goals Meet Multiregional Trials" by Drs. Gautam Mehta, Richard Pazdur, Namandje Bumpus and Robert Califf.

🇪🇺The European Commission has officially approved the first certification schemes for #RFNBOs (Renewable Fuels of Non-Biological Origin), including hydrogen!

What does this mean?

🌍 Renewable gases and fuels, including hydrogen, can now be officially certified as “green” according to EU standards.

💡 Hydrogen producers across Europe and beyond can now apply for certification under the EU’s new framework and meet the standards necessary to access funding and contribute to the EU’s ambitious renewable energy goals.

The approved schemes are:

🔹 REDcert-EU

🔹 ISCC EU

🔹 CertifHy

This is a pivotal moment in accelerating the adoption of clean energy solutions across Europe. Now, renewable hydrogen producers worldwide can certify their products, making them eligible for recognition across all EU Member States.

The info came from him. Whether it is part of the FDA AI request remains unclear. You wonder how much AI is required before the FDA make their decision.

Https://www.sciencedirect.com/science/article/pii/S2772487524001156

Aye Don

“ As of 30 September 2024, and as at the current date, a total of 26.94m warrants remain outstanding, with a subscription value of up to approx. £6 million, as set out in the table below.”

26,943,757 - 887,500 = 26,056,257 to go.

13,612,088 @ 25p expire 21 March 2025 £3,403,022

8,140,000 @ 20p expire 28 July 2025 £1,628,000

Who do you think is forward selling into the rise from 15p to 42p Xer58 ?

Rampers ? “Those big trades were buys” right ?

If the selling continues next stop 32.7 then 30.5 then 27.7.

If 27.7 goes who knows.

If there’s a RNS like Nationwide Mutual expand to 44 states (as with Ting) or a new US player comes on board it’ll reverse.

Do the FIB numbers Xer58. I bought in and banked profit. I will buy in again because this is a potential multi bagger from 15p

Fib retrace. I posted If 38 goes then it’s back to 35p and here it is. I also posted where it could go if 35p goes.

Depends on buyer sentiment, warrant flippers clearing and news.

I’m glad i banked the profit. I can buy more lower now. Or trade something else.

Beware the RAMPERS saying the big sells are buys. And beware the RAMPERS shouting long n strong while they sell.

Good luck. This looks good. I can still miss a few percentage rise before buying back in.

Watchout for Late reported trades 100k showing as "buys" etc. And the posters saying "Big buys after hours" or "Those are large buys going through" etc etc

If 35 goes next stop 32.7 then 30 if the buyers don’t jump in and the selling continues.

Sells going by the share price. If this doesn’t spike at least 10% on open then it’ll confirm if they are buys or sells.